News and Trends 24 Oct 2025 The ESMO 2025 digest: Is oncology in good shape? The 2025 edition of the European Society for Medical Oncology (ESMO) was held this week in Berlin, delve into its key highlights. October 24, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 May 2025 Seven lung cancer companies advancing new treatments in 2025 Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to bispecific antibodies. May 20, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Reports Produced by Inpart 19 May 2025Oncology R&D trends and breakthrough innovations Explore the latest in oncology R&D with Inpart’s new trends report, featuring emerging technologies, breakthrough innovations, and expert insights shaping the future of cancer research. May 19, 2025 Share WhatsApp Twitter Linkedin Email Produced by Inpart
In Depth 30 Apr 2025 The future of NSCLC treatment: what’s in store for the therapeutic space? Here we delve into the different kinds of NSCLC therapies in the running to potentially address late-stage cancer that is often difficult to treat. April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2023 Lung cancer research: five advancements over the past year Lung cancer is the second most common cancer worldwide, with more than 2.2 million new cases of lung cancer being reported in 2020. Survival rates depend on the stage of diagnosis, and, according to statistics from Cancer Research UK, in England, more than 55% of people with stage 1 lung cancer survive for five years […] July 10, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 New data on breath biopsy for early detection of lung cancer Owlstone Medical has announced new data on the development of a screening test for the early detection of lung cancer. The results and research progress were presented in two posters at the EACR 2023 Congress, the annual meeting of the European Association for Cancer Research, held June 12-15 in Torino, Italy. The poster ‘Proof-of-mechanism study […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 DeuterOncology closes financing round to start lung cancer study DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […] January 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023 Ofer Sharon is the CEO of OncoHost, a biotech company in the precision oncology space. A physician by training, Sharon has leveraged his experience in pharma drug development and entrepreneurship to lead OncoHost through the development of PROphet, the company’s host response profiling platform, which will launch in the U.S. for non-small cell lung cancer […] December 14, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 PDC*line Pharma presents first immunological results from trial with PDC*lung01 PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […] December 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Lyvgen and Bristol Myers Squibb commitment to transform cancer care Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […] November 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Legend Biotech small cell lung cancer drug gets FDA ok for clinical development Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […] November 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email